Press Releases

Investor Resources
Contact Us
Investor ResourcesPress Releases

Press Releases

Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis


November 1, 2023

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement


October 20, 2023

Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction


October 10, 2023

Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare Conference


September 26, 2023

Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx™ for the Treatment of Acute Myocarditis


September 19, 2023

Cardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference


August 9, 2023

Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market


August 8, 2023

Cardiol Therapeutics Reports Results of 2023 Annual General Meeting


June 29, 2023

Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 p.m. EDT


June 27, 2023

2025 Cardiol Therapeutics. All right reserved.